MIAMI--(BUSINESS WIRE)--July 6, 2006--DOR BioPharma, Inc. (OTCBB:DORB - News; “DOR” or the “Company”), announced today that it has successfully completed its cGMP (current Good Manufacturing Practices) milestone for the production of RiVax(TM), DOR’s vaccine against ricin toxin. The milestone was achieved in the performance of a Challenge Grant totaling $6.4 million previously awarded to DOR in September 2004 by the National Institute of Allergy and Infectious Diseases (NIAID), a unit of the National Institutes of Health. The safety and immunogenicity of RiVax(TM) has recently been evaluated in a Phase I clinical trial in healthy volunteers, and the results were published earlier this year in the Proceedings of the National Academy of Sciences.
